Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01

Trial Profile

Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2016 Planned End Date changed from 1 Nov 2021 to 1 Dec 2016.
    • 05 Dec 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2016.
    • 05 Dec 2016 Planned initiation date changed from 1 Nov 2015 to 1 Feb 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top